Insider Buying: Andean Precious Metals Corp. (CVE:APM) Insider Acquires 700,000 Shares of Stock

Andean Precious Metals Corp. (CVE:APM - Get Free Report) insider 2176423 Ontario Ltd. purchased 700,000 shares of the business's stock in a transaction on Tuesday, September 24th. The stock was purchased at an average cost of C$1.36 per share, with a total value of C$952,000.00.

2176423 Ontario Ltd. also recently made the following trade(s):

• On Monday, September 16th, 2176423 Ontario Ltd. purchased 204,600 shares of Andean Precious Metals stock. The stock was purchased at an average cost of C$1.14 per share, with a total value of C$233,141.70.

Andean Precious Metals Stock Down 4.9 %

Shares of APM traded down C$0.07 during trading hours on Wednesday, hitting C$1.36. 159,858 shares of the stock traded hands, compared to its average volume of 166,869. Andean Precious Metals Corp. has a 1-year low of C$0.53 and a 1-year high of C$1.49. The stock has a market capitalization of C$203.13 million, a price-to-earnings ratio of 3.58 and a beta of 1.13. The firm has a fifty day simple moving average of C$1.06.

Andean Precious Metals (CVE:APM - Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The company reported C$0.08 earnings per share (EPS) for the quarter, meeting the consensus estimate of C$0.08. Andean Precious Metals had a return on equity of 41.08% and a net margin of 23.75%. The business had revenue of C$95.47 million for the quarter. As a group, equities research analysts expect that Andean Precious Metals Corp. will post 0.3801917 earnings per share for the current year.

Analyst Ratings Changes

Separately, Desjardins increased their target price on Andean Precious Metals from C$1.60 to C$1.70 and gave the stock a "buy" rating in a report on Tuesday, September 3rd.

About Andean Precious Metals

Aptorum Group Limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diseases with a focus on infectious diseases and cancers. Its pipeline enables the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases.